Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis

Ning, Nian-zhi; Li, Tao; Zhang, Ju-ling; Qu, Fen; Huang, Jie; Liu, Xiong; Li, Zhan; Geng, Wei; Fu, Jun-liang; Huan, Wang; Zhang, Shu-yong; Bao, Chun-mei; Wang, Hui

doi:10.1186/s12879-018-3101-1

BMC Infectious Diseases

Table 3 Risk factors for BA episodes progressing to SBP

From: Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis

	Progress to SBP (n = 45)	No progress to SBP (n = 142)	Univariate analysis		Multivariate analysis
	Progress to SBP (n = 45)	No progress to SBP (n = 142)	P	Odds ratio (95% CI)	P	Odds ratio (95% CI)
Sex (male)	37 (82.2%)	108 (76.1%)	0.390	0.687 (0.292–1.616)	–	–
Age (yr)	52.4 ± 9.2	55.4 ± 12.5	0.144	0.979(0.951–1.007)	–	–
Nosocomial infection	23 (51.1%)	57 (40.1%)	0.197	1.559 (0.795–3.059)	–	–
MELD score	23.0 ± 10.7	16.3 ± 7.4	< 0.001	1.089 (1.046–1.133)	0.503	1.036 (0.934–1.149)
Days between admission and onset of infection	3 (0–7.5)	1 (0–6)	0.239	1.018 (0.989–1.048)	–	–
Fever	30 (66.7%)	69 (48.6%)	0.036	2.116 (1.049–4.268)	0.053	2.533 (0.986–6.505)
Chills	4 (8.9%)	11 (7.7%)	0.806	1.162 (0.351–3.846)	–	–
Abdominal pain	15(33.3%)	34 (23.9%)	0.214	1.588(0.765–3.295)	–	–
ALT(U/L)	42.0 (24.0–106.0)	30.0 (20.0–49.0)	0.011	1.005 (1.001–1.009)	0.326	1.004 (0.996–1.011)
AST(U/L)	70.0 (42.0–135.5)	52.5 (33.0–88.5)	0.030	1.003(1.000–1.005)	0.602	1.001(0.996–1.006)
Prealbumin(mg/L)	41.3 ± 22.7	56.1 ± 24.8	0.001	0.973 (0.957–0.989)	0.224	0.986 (0.965–1.008)
Prothrombin time(S)	19.2 (15.7–31.1)	16.3 (14.1–19.3)	< 0.001	1.078 (1.034–1.125)	0.118	1.064 (0.984–1.149)
Bun(mmol/L)	8.6 (5.5–13.9)	6.6 (4.8–11.5)	0.074	1.039 (0.996–1.083)	–	–
Serum PMN(cells/μL)	4.9 (2.8–9.8)	4.2 (2.4–6.6)	0.002	1.12 (1.042–1.205)	0.161	1.641 (0.822–3.277)
Serum WBC(cells/μL)	6.1 (4.0–11.8)	5.4 (3.6–8.5)	0.006	1.096 (1.027–1.17)	0.223	0.671 (0.353–1.275)
Serum creatinine (μmol/L)	105.0 (82.0–159.0)	88.5 (70.8–113.5)	0.15	1.003 (0.999–1.006)	–	–
Total protein(g/L)	56.0 (50.0–61.0)	55.0 (50.0–63.0)	0.679	0.997 (0.983–1.011)	–	–
Total bilirubin (μmol/L)	98.5 (43.9–311.4)	51.9 (32.4–140.2)	0.018	1.002 (1.000–1.005)	0.36	0.998 (0.994–1.002)
Ascitic PMN(cells/μL)	64.7 (21.7–141.7)	24.0 (5.3–74.8)	0.002	1.008 (1.003–1.013)	0.029	1.007 (1.001–1.013)
Ascitic WBC(cells/μL)	257.0(114.5–370.0)	161.0 (91.8–302.8)	0.529	1.000(0.999–1.002)	–	–
hepatocellular carcinoma	20 (44.4%)	39 (27.5%)	0.035	2.113 (1.056–4.229)	0.024	3.047 (1.161–7.997)
hepatic encephalopathy	16(35.6%)	43(30.3%)	0.508	1.27(0.626–2.577)	–	–
septic shock	12(26.7%)	16 (11.3%)	0.014	2.864 (1.235–6.639)	0.799	0.851 (0.246–2.949)
Gastrointestinal haemorrhage	11 (24.4%)	29 (20.4%)	0.567	1.261 (0.57–2.786)	–	–
diabetes mellitus	7 (15.6%)	28(19.7%)	0.534	0.75 (0.303–1.856)	–	–

P-values < 0.05 and corresponding Odds ratio are indicated in bold

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com